Cingulate (CING) Competitors $4.28 -0.07 (-1.49%) As of 03:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. HOWL, IMMX, IPSC, ITRM, OTLK, OKYO, VRCA, ATNM, RPTX, and IBIOShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Werewolf Therapeutics (HOWL), Immix Biopharma (IMMX), Century Therapeutics (IPSC), Iterum Therapeutics (ITRM), Outlook Therapeutics (OTLK), OKYO Pharma (OKYO), Verrica Pharmaceuticals (VRCA), Actinium Pharmaceuticals (ATNM), Repare Therapeutics (RPTX), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Werewolf Therapeutics Immix Biopharma Century Therapeutics Iterum Therapeutics Outlook Therapeutics OKYO Pharma Verrica Pharmaceuticals Actinium Pharmaceuticals Repare Therapeutics iBio Werewolf Therapeutics (NASDAQ:HOWL) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Is HOWL or CING more profitable? Cingulate has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Werewolf Therapeutics' return on equity of -58.83% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics-578.80% -58.83% -38.45% Cingulate N/A -570.20%-236.15% Do insiders and institutionals believe in HOWL or CING? 64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 21.1% of Werewolf Therapeutics shares are held by insiders. Comparatively, 17.1% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to HOWL or CING? In the previous week, Cingulate had 4 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 7 mentions for Cingulate and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.93 beat Cingulate's score of 0.67 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in HOWL or CING? Werewolf Therapeutics received 23 more outperform votes than Cingulate when rated by MarketBeat users. However, 78.57% of users gave Cingulate an outperform vote while only 70.83% of users gave Werewolf Therapeutics an outperform vote. CompanyUnderperformOutperformWerewolf TherapeuticsOutperform Votes3470.83% Underperform Votes1429.17% CingulateOutperform Votes1178.57% Underperform Votes321.43% Do analysts recommend HOWL or CING? Werewolf Therapeutics currently has a consensus target price of $9.00, suggesting a potential upside of 820.25%. Cingulate has a consensus target price of $16.00, suggesting a potential upside of 273.40%. Given Werewolf Therapeutics' higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Cingulate.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher valuation and earnings, HOWL or CING? Cingulate has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$1.89M23.26-$37.37M-$1.66-0.59CingulateN/AN/A-$23.53M-$14.64-0.29 Which has more risk & volatility, HOWL or CING? Werewolf Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.83, meaning that its stock price is 183% less volatile than the S&P 500. SummaryWerewolf Therapeutics beats Cingulate on 10 of the 17 factors compared between the two stocks. Remove Ads Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulatePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.00M$6.87B$5.61B$7.68BDividend YieldN/A2.79%5.33%4.02%P/E RatioN/A7.3523.5018.55Price / SalesN/A208.36376.0088.66Price / CashN/A65.6738.1734.64Price / Book-0.066.256.814.11Net Income-$23.53M$142.34M$3.20B$247.18M7 Day Performance10.66%-8.43%-5.42%-4.05%1 Month Performance5.83%-9.99%-0.12%-6.41%1 Year Performance296.36%-12.60%7.61%-2.08% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate3.0837 of 5 stars$4.29-1.5%$16.00+273.4%+295.5%$13.78MN/A-0.2920Upcoming EarningsShort Interest ↓HOWLWerewolf Therapeutics2.6962 of 5 stars$1.12-0.9%$9.00+703.6%-84.1%$50.21M$1.89M-0.7340IMMXImmix Biopharma2.7192 of 5 stars$1.82+1.1%$7.00+284.6%-44.6%$50.07MN/A-2.149Earnings ReportPositive NewsIPSCCentury Therapeutics2.2893 of 5 stars$0.58+5.2%$5.00+756.6%-87.7%$49.63M$6.59M-0.32170Analyst ForecastITRMIterum Therapeutics2.0758 of 5 stars$1.43-0.7%$5.00+249.7%-18.2%$49.45MN/A-1.0910Positive NewsOTLKOutlook Therapeutics1.5538 of 5 stars$1.50-1.0%$10.20+582.3%-88.9%$48.35MN/A-0.2020Positive NewsGap DownOKYOOKYO Pharma3.195 of 5 stars$1.42+5.2%$7.00+393.0%-9.4%$48.05MN/A0.007Short Interest ↓News CoveragePositive NewsGap UpVRCAVerrica Pharmaceuticals4.1455 of 5 stars$0.52-6.4%$9.50+1,719.6%-92.7%$47.92M$7.57M-0.2940ATNMActinium Pharmaceuticals1.7483 of 5 stars$1.49-3.9%$7.40+396.6%N/A$46.48M$81,000.00-1.0730Analyst RevisionNews CoverageGap DownRPTXRepare Therapeutics3.3789 of 5 stars$1.08-3.6%$4.50+316.7%-77.7%$45.91M$53.48M-0.54180IBIOiBio0.5637 of 5 stars$4.63flat$4.30-7.1%+1.5%$45.72M$375,000.000.00100Gap Up Remove Ads Related Companies and Tools Related Companies Werewolf Therapeutics Competitors Immix Biopharma Competitors Century Therapeutics Competitors Iterum Therapeutics Competitors Outlook Therapeutics Competitors OKYO Pharma Competitors Verrica Pharmaceuticals Competitors Actinium Pharmaceuticals Competitors Repare Therapeutics Competitors iBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
